Abstract
Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
Highlights
The paper entitled “Lenalidomide in diffuse large B-cell lymphoma” by C
Lenalidomide was designed to enhance immunologic and anticancer properties while potentially decreasing neurotoxic and teratogenic adverse effects of the parent compound thalidomide. The introduction of this novel agent has broadened the therapeutic landscape of hematologic malignant disorders including multiple myeloma (MM) and, more recently, other B-cell neoplasms
We focused on mechanisms of action and results from clinical investigation that report the relevance of lenalidomide for the treatment of B-cell disorders including MM, chronic lymphocytic leukaemia (CLL), and non-Hodgkin’s lymphomas by offering new mechanisms for targeting these diseases
Summary
The paper entitled “Lenalidomide in diffuse large B-cell lymphoma” by C. Anna Marina Liberati,[1] Umberto Vitolo,[2] Antonio Palumbo,[2] and Agostino Cortelezzi[3] The introduction of this novel agent has broadened the therapeutic landscape of hematologic malignant disorders including multiple myeloma (MM) and, more recently, other B-cell neoplasms.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
